Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

England's National Health Service said Friday it is the first health system in the world to offer a targeted blood cancer ...

A new study from UCLA Health suggests COVID vaccines may protect patients from severe kidney damage. The study found ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

President Donald Trump has already eroded many of the U.S.’s democratic safeguards and traditions in the initial months of ...

Montrose became Houston’s LGBTQ+ stronghold in the 20th century, but as the city grows, the queer community is expanding ...

Eli Lilly’s revenue has soared in recent years thanks to its leadership in the weight loss drug market. Eli Lilly (NYSE: LLY) ...

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...